This is a Phase 1, 2-part double-blinded (with respect to NX-5948/placebo), placebo-controlled study. Part 1 is a randomized, 3 period cross-over food-effect (FE) and drug-drug interaction (DDI) study. Part 2 is a single-period PK evaluation study.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Part 1 Food Effect: AUC0-t for NX-5948 administered under fed and fasted conditions
Timeframe: 9 weeks
Part 1 Food Effect: AUC0-inf for NX-5948 administered under fed and fasted conditions
Timeframe: Approximately 9 weeks
Part 1 Food Effect: Cmax for NX-5948 administered under fed and fasted conditions
Timeframe: 9 weeks
Part 1 Drug Drug Interaction: AUC0-inf for NX-5948 administered with and without fluconazole
Timeframe: 9 weeks
Part 1 Drug Drug Interaction: Cmax for NX-5948 administered with and without fluconazole
Timeframe: 9 weeks
Part 1 Drug Drug Interaction: AUC0-t for NX-5948 administered with and without fluconazole
Timeframe: Approximately 9 weeks
Part 2 PK: AUC0-inf for NX-5948 administration
Timeframe: 6 weeks
Part 2 PK: Cmax for NX-5948 administration
Timeframe: 6 weeks
Part 2 PK: AUC0-t for NX-5948 administration
Timeframe: Approximately 6 weeks